

Pain Therapeutics

Drugs, Markets & Companies

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

December 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and received graduate training in both Europe and US. He has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. During his active neurosurgical career, Prof. Jain was involved in the management of pain. He has been working in the biotechnology/biopharmaceuticals industry for several years and currently is the CEO at Jain PharmaBiotech.

Prof. Jain is an Associate Editor of MedLink Neurology, an electronic encyclopedia of neurology published by Medlink Corporation (San Diego, California) where he is also the author in charge of writing and yearly update of 161 articles including those on treatment of pain.

Prof. Jain's 473 publications including 28 books (5 as editor + 23 as author) and 50 special reports which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. He has also written a textbook of gene therapy, which is the first book on this subject to be translated into the Chinese language. A book on gene therapy companies was published in 2000 by John Wiley & Sons and the updated version has been incorporated into a report on Gene Therapy published by Jain PharmaBiotech in 2014. Prof. Jain has edited "Drug Delivery Systems" (Humana/Springer 2008, 2nd ed 2014) and "Drug Delivery to the Central Nervous System" (Humana/Springer 2010). His other recent books include "Handbook of Nanomedicine" (Springer/Humana 2008; Chinese edition, Peking University Press 2011, 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer, 2017), "Handbook of Neuroprotection" (Springer 2011), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer, January 2014). He has edited "Applied Neurogenomics" (Springer 2015).

The pain report is an update with inclusion of commercial information in an earlier publication titled "Pain Therapeutics: A strategic re-evaluation" published by Reuter's Business Insight/Datamonitor UK in 2000. Other reports written by Prof. Jain in the past have been published by PJB Publications, D & MD, Informa, and Decision Resources Inc. This is one of the in-house publications of Jain PharmaBiotech that are constantly updated.

December 2017
Copyright ©2017 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	19
1. Basic Aspects of Pain	21
Introduction	21
Historical aspects of pain	21
Pain definitions	23
A glossary of terms relevant to pain	24
Pain classification and description	24
Neuropathic pain	25
<i>Refractory neuropathic pain</i>	<i>26</i>
<i>Classification of neuropathic pain according to levels</i>	<i>26</i>
Cancer pain	27
<i>Bone pain in cancer</i>	<i>29</i>
Complex regional pain syndrome	30
Mechanisms of pain	30
Pain pathways	30
<i>Role of nociceptors in pain transmission</i>	<i>32</i>
Gate control and neuromatrix theories of pain	32
Pain mediators	33
Modulation of pain by pictures associated with social contacts	34
Modulation of pain by emotions	34
Role of the sympathetic nervous system in pain	34
Visceral pain	34
<i>Pathomechanism of visceral pain</i>	<i>35</i>
Pathomechanism of neuropathic pain	35
<i>Role of intact nerve fibers in neuropathic pain</i>	<i>35</i>
<i>Chemokines as mediators of neuropathic pain</i>	<i>35</i>
<i>Chemotherapy-induced neuropathic pain</i>	<i>36</i>
<i>CNS innate immunity and neuropathic pain</i>	<i>36</i>
<i>Cytokines as mediators of neuropathic pain</i>	<i>36</i>
<i>Free radicals in generation of neuropathic pain</i>	<i>37</i>
<i>GABA deficiency in neuropathic pain</i>	<i>37</i>
<i>Genetic basis of neuropathic pain</i>	<i>37</i>
<i>Gene expression changes in neuropathic pain</i>	<i>37</i>
<i>Glial activation and neuropathic pain</i>	<i>38</i>
<i>Immune cell-derived opioids and neuropathic pain</i>	<i>39</i>
<i>Spinal leptin and neuropathic pain</i>	<i>39</i>
<i>Tetrahydrobiopterin regulates neuropathic pain sensitivity</i>	<i>39</i>
Pathomechanism of migraine	39
Role of the immune system in pain	40
Pain and itch	41
<i>Pathomechanism of itch</i>	<i>41</i>
<i>Clinical aspects of itch</i>	<i>42</i>
Molecular pathophysiology of pain	42
Role of ion channels in pain	42
<i>Acid-sensing ion channels</i>	<i>43</i>
<i>Calcium channels in pain</i>	<i>43</i>
<i>P2X3 ion channels</i>	<i>44</i>
<i>Potassium ion channels</i>	<i>44</i>
<i>Sodium ion channels in pain</i>	<i>44</i>
<i>TRP ion channels in pain</i>	<i>45</i>
Genetic basis of pain	46
<i>Alternative RNA splicing and pain</i>	<i>47</i>
<i>Study of genes in pain</i>	<i>48</i>
<i>Pain as a channelopathy</i>	<i>48</i>
Pain in the brain	48
<i>Effect of chronic pain on opioid receptors in the brain</i>	<i>49</i>
<i>Neuropathic pain-induced morphological changes in the brain</i>	<i>49</i>
Change from acute to chronic pain	49
<i>Acute versus chronic pain</i>	<i>50</i>
<i>Descending facilitatory modulation of pain</i>	<i>50</i>
<i>Development of chronic pain following severe accidental injury</i>	<i>50</i>
<i>Pain and transcriptional repressor DREAM</i>	<i>51</i>
<i>Role of neuronal plasticity in pain</i>	<i>51</i>
<i>Role of epigenetics in development of chronic pain</i>	<i>52</i>
<i>Concluding remarks on evolution of acute pain into chronic pain</i>	<i>52</i>
Neurochemistry of pain	52
<i>Molecular elements of pain in the peripheral nervous system</i>	<i>52</i>

<i>Molecular elements of pain in the central nervous system</i>	53
<i>Opioid receptors</i>	53
<i>Role of AMPA receptors in chronic pain</i>	54
<i>Kinins</i>	54
<i>Serotonin</i>	55
<i>Substance P</i>	55
<i>Excitatory amino acids</i>	55
<i>Role of nitric oxide in pain</i>	55
<i>Prostaglandins</i>	56
<i>Endocannabinoids</i>	57
<i>Protein kinase C</i>	57
<i>Adenosine and adenosine receptors</i>	57
<i>Vitamin D and pain</i>	58
<i>Vanilloid receptor</i>	58
<i>TRPA₁ and TRPV₁ receptors</i>	58
<i>Endothelin-B receptors</i>	60
<i>Nerve growth factor and pain</i>	60
<i>Adrenomedullin as a pain-related peptide</i>	60
Biomarkers of pain	61
<i>Biomarkers of visceral pain</i>	61
2. Assessment of Pain and Analgesics	63
Introduction	63
Animal models of pain	63
An overview	63
Selection of animal species as models for pain	63
Types of noxious stimuli	64
Animal models of neuropathic pain	64
Animal models of arthritis	64
Animal models of peripheral neuropathy	65
Limitations of current pain models	65
NeuroDigm GEL Model™ of neuropathic pain	66
Ethical issues concerning animal pain models	66
Medical evaluation of pain	67
Chronic pain as a manifestation of various diseases	67
Assessment of pain patients	67
Medical examination	67
Measurement of pain	68
Quality of pain intensity assessment in clinical research studies	69
Quantitative sensory testing	70
Pain measurement tools for neonates and children	70
Quantitative sensory testing	71
Microneurographic recordings	71
Psychological assessment of pain	72
Testing for in vivo pain processing	72
Brain imaging in pain	72
<i>fMRI for study of pain</i>	72
<i>PET for study of pain</i>	72
<i>PET correlated with fMRI and evoked potentials</i>	73
Patient outcomes and quality of life during treatment for chronic pain	73
Collection and analysis of data on pain patients	74
Evaluation of analgesics in humans	74
Early phase clinical trials of analgesics in humans	74
Design of clinical trials for pain	75
Assessment of neuropathic pain	76
Transdermal electrical stimulation for study of chronic pain	76
Placebo effect in pain	77
Role of electronic pain recording in determination of the placebo effect	77
Outcome measures for chronic pain trials	77
Pain, pain therapies and cognitive function	78
3. Pharmacotherapy of Pain	79
Introduction	79
Mechanism of action of currently used pain medications	79
Non-steroidal antiinflammatory drugs	80
COX-2 inhibitors	80
<i>Celecoxib</i>	81
<i>Metamizole</i>	82
<i>Nimesulide</i>	82
<i>Rofecoxib</i>	82
<i>Valdecoxib</i>	83

<i>Lumiracoxib</i>	83
<i>Side effects of COX inhibitors</i>	83
<i>Innovative COX-2 inhibitors in development</i>	85
Acetaminophen.....	86
Antioxidants as analgesics.....	86
Opiates and opioids	86
Morphine	87
Codeine	87
Tramadol	88
Innovations in opioid therapy	88
<i>Oral transmucosal fentanyl</i>	89
<i>Use of opioids for chronic non-cancer pain</i>	89
Opioid receptor modulation for visceral pain	89
Opiorphin.....	90
N-methyl-D-aspartate receptor antagonists	90
Ketamine	90
CNS 5161	91
Triptans for treatment of non-migrainous pain.....	91
Capsaicin	91
NGX-4010.....	92
Local anesthetics	92
Topical application	92
Nerve blocks	92
<i>Injection of local anesthetics for analgesia</i>	93
<i>Ultrasound-guided nerve blocks</i>	93
Topical salicylates for the treatment of pain.....	93
Topical rubefacients for acute and chronic pain in adults	93
Adjunctive analgesics	94
Antidepressants.....	94
<i>Mechanism of analgesic action of antidepressants</i>	95
Antiepileptic drugs	96
<i>Mechanism of action of antiepileptic drugs in neuropathic pain</i>	97
<i>Carbamazepine</i>	97
<i>Gabapentin</i>	98
<i>Lamotrigine</i>	98
<i>Phenytoin</i>	99
<i>Pregabalin</i>	99
<i>Topiramate</i>	100
<i>Valproic acid</i>	100
<i>Other antiepileptic drugs</i>	100
Clonidine.....	101
Baclofen.....	101
Corticosteroids	102
Calcitonin.....	102
Bisphosphonates	102
Botulinum toxins	103
Analgesic effect of botulinum toxin A	103
Engineered botulinum toxin	103
Analgesics from traditional medical systems	104
Herbs and other plants	104
Analgesics derived from cobra toxin	105
4. Management of Pain	107
Introduction	107
Sites for pain management.....	107
Self-medication at home	107
Physicians' offices	107
Major hospitals	107
Pain centers	108
Non-pharmacological approaches to pain	108
Alternative medicine.....	108
<i>Acupuncture</i>	109
<i>Aromatherapy</i>	109
<i>Self-Controlled Energo Neuro Adaptive Regulation</i>	110
Behavioral therapy.....	110
<i>Cognition and pain</i>	110
<i>Control over brain activation and pain by using functional MRI</i>	110
<i>Mindfulness meditation for relief of chronic pain</i>	111
<i>Thermal-grill illusion</i>	111
<i>Virtual reality therapy</i>	111
Local application of heat	111

Transcutaneous nerve stimulation.....	112
Non-invasive brain stimulation techniques for chronic pain.....	112
<i>Transcranial magnetic stimulation</i>	112
<i>Cranial electrotherapy stimulation</i>	113
Neurosurgery for pain relief.....	113
<i>Ablative procedures on the nervous system</i>	113
<i>Procedures on peripheral, spinal and cranial nerves</i>	113
<i>Vagal nerve stimulation for control of pain</i>	114
<i>Neuromodulation</i>	114
<i>Spinal cord stimulation</i>	115
<i>Brain stimulation</i>	116
<i>Implantation of drug delivery devices</i>	117
Management of special types of pain.....	117
Acute pain.....	117
<i>Management of acute renal colic: NSAIDs vs. opioids</i>	117
<i>Combination of opioids and NSAIDs for acute pain</i>	117
<i>Reasons for inadequate management of acute pain</i>	118
Perioperative pain management.....	118
<i>Devices for delivery of analgesics in the postoperative period</i>	119
<i>Drug combination for perioperative pain</i>	120
<i>Gabapentin for reduction of postoperative pain</i>	120
<i>Ketamine for perioperative pain</i>	120
<i>Opioids for perioperative pain</i>	121
<i>Perioperative pain in neurosurgery</i>	121
<i>Prolonged duration local anesthesia</i>	122
<i>Concluding remarks on the management of postoperative pain</i>	122
Pain in the intensive care unit.....	122
Pain associated with sports and exercise.....	123
Pain associated with trauma.....	123
Chronic pain and sleep.....	124
Chronic abdominal pain.....	124
Functional somatic syndromes.....	124
Fibromyalgia syndrome.....	125
<i>Pathomechanism of FMS</i>	125
<i>Management of FMS</i>	126
<i>Non-pharmacological therapies for FMS</i>	126
<i>Pharmacotherapy of FMS</i>	126
<i>Concluding remarks on management of FMS</i>	128
Erythromelalgia.....	128
Irritable bowel syndrome.....	129
<i>Opioids for IBS</i>	129
<i>Pregabalin for IBS</i>	130
<i>Tricyclic antidepressants for IBS</i>	130
<i>Serotonin-modulating drugs for IBS</i>	130
Musculoskeletal pain.....	130
Myofascial pain syndrome.....	131
<i>Non-pharmacological methods of treatment of MPS</i>	131
<i>Pharmacotherapy of MPS</i>	131
Osteoarthritis.....	133
<i>Pain aggravates osteoarthritis by crosstalk between CNS and the joint</i>	133
<i>Management of osteoarthritis</i>	134
Rheumatoid arthritis.....	135
<i>Management of pain in rheumatoid arthritis</i>	135
<i>Disease modifying therapies in rheumatoid arthritis</i>	135
<i>Resurgence of interest in gold-based treatments for RA</i>	137
Backache and sciatica.....	137
<i>Lumbar disc disease and sciatica</i>	138
<i>Management of back pain with analgesics</i>	139
<i>Miscellaneous medical therapies for backache and sciatica</i>	140
Neck pain.....	140
Chronic pelvic pain.....	141
<i>Prostatitis</i>	141
Cancer pain.....	141
<i>Adjuvant drugs for cancer pain</i>	142
<i>Alternative non-pharmacological methods</i>	142
<i>Anesthetic techniques</i>	142
<i>Management of bone pain in cancer</i>	143
<i>Non-opioid analgesics for cancer pain</i>	143
<i>Opioid treatment of cancer pain</i>	143
<i>Opioid breakthrough pains</i>	145
<i>Opioid-induced enhancement of cancer growth and its prevention</i>	145

<i>Opioids delivery methods for cancer pain</i>	145
<i>Opioid administration through implanted drug delivery devices</i>	146
<i>Radiation therapy</i>	146
<i>Surgical methods of cancer pain relief</i>	147
<i>Conclusions regarding management of cancer pain</i>	147
Chronic non-malignant pain	147
Headache	148
<i>Cluster headache</i>	149
<i>Chronic daily headache</i>	149
<i>Indomethacin-responsive headache</i>	150
<i>Occipital neuralgia</i>	150
<i>Paroxysmal hemicrania</i>	151
<i>Tension headache</i>	151
Migraine	151
<i>Management of acute migraine</i>	152
<i>Pediatric migraine</i>	155
<i>Status migrainosus</i>	156
<i>Migraine prophylaxis</i>	156
<i>Non-pharmacological approaches to migraine</i>	157
Trigeminal neuralgia	159
Dental pain	159
Neuropathic pain	160
<i>Pathogenesis of neuropathic pain</i>	160
<i>Chronobiology of neuropathic pain as guide to therapy</i>	161
<i>Management of neuropathic pain based on mechanism</i>	161
<i>Guidelines for the management of neuropathic pain</i>	161
<i>Pharmacotherapy of neuropathic pain</i>	162
<i>Evidence-based management of neuropathic pain</i>	164
Management of central neuropathic pain	164
<i>Neurosurgical approaches to central neuropathic pain</i>	165
<i>Management of neuropathic pain in syringomyelia</i>	165
<i>Neuropathic pain associated with spinal cord injury</i>	165
Peripheral neuropathic pain	166
<i>Truncal neuropathic pain</i>	166
<i>Management of postsurgical peripheral neuropathic pain</i>	166
<i>Management of chemotherapy-induced pain</i>	167
<i>Morton's neuroma</i>	167
<i>Management of peripheral diabetic neuropathy</i>	168
<i>Postherpetic neuralgia</i>	169
<i>Complex regional pain syndrome</i>	171
<i>An algorithm for the management of peripheral neuropathic pain</i>	173
Phantom limb pain	173
<i>Pathomechanism of phantom limb pain</i>	174
<i>Management of phantom limb pain</i>	174
Painful neuromas following amputation	176
Pain and depression	176
<i>Neurochemical link between pain and depression</i>	177
<i>Management of chronic pain and depression</i>	178
Miscellaneous painful conditions	178
<i>Burning mouth syndrome</i>	178
<i>Chronic unstable angina</i>	179
<i>Mastalgia</i>	179
<i>Ophthalmic pain</i>	180
<i>Pain in Parkinson's disease</i>	180
Pain in sickle cell disease	180
Management of chronic unexplained pain	181
Management of itching	181
<i>Topical applications for itching</i>	182
<i>Systemic therapies for itching</i>	183
<i>Non-pharmacological therapies for itch</i>	183
Management of pain in special population groups	184
<i>Racial and ethnic differences in pain management</i>	184
<i>Pain in neonates</i>	184
<i>Management of pain in children</i>	184
<i>Misuse of codeine in children</i>	186
<i>Management of pain in the elderly</i>	186
<i>Management of pain in women</i>	187
<i>Reasons for increased pain perception in women</i>	187
<i>Chronic pelvic pain in women</i>	188
<i>Gender differences in response to analgesics</i>	188
<i>Considerations for pain management in women</i>	188

Management of pain in neurologically handicapped persons	189
Management of pain in the cognitively impaired elderly people	189
Management of pain in brain-damaged minimally conscious patients	190
Management of pain in the terminally ill	190
Problems in the management of pain	191
Inadequate pain management	191
Problems with use of opioids	191
<i>Guideline for use of opioids</i>	192
<i>Opioid regulations</i>	193
<i>Opioids alternatives</i>	193
Excessive prescription of gabapentinoids	194
<i>Problems with use of gabapentinoids</i>	194
Suggestions for improvement of pain management by healthcare providers	195
<i>Management of neuropathic pain refractory to first line treatment</i>	196
<i>Multidisciplinary approaches to pain management</i>	197
<i>Pain as the fifth vital sign</i>	197
<i>Reassessment of management of chronic pain</i>	197
5. Drug Delivery for Pain	199
Introduction	199
Intra-articular injection for relief of joint pain	200
Delivery of analgesics to peripheral nerves	200
Controlled release drug delivery for pain	201
Accelerating the effect of subcutaneous morphine	201
Controlled drug delivery at site of pain	201
Oral extended release opioids	202
<i>Extended release oral morphine</i>	202
<i>Controlled release oxycodone</i>	202
<i>Extended release oxymorphone</i>	202
<i>Oral extended release tramadol</i>	203
Extended release gabapentin	203
Use of nanotechnology for drug delivery for pain	204
Non-injection methods of delivery of analgesics	204
Topical applications for pain	205
<i>Topical local anesthetics</i>	205
<i>Topical NSAIDs</i>	205
<i>Topical and transdermal diclofenac</i>	206
<i>Topical application for postoperative pain</i>	206
Needle-free drug delivery for pain	207
<i>Glide SDI® solid dose injector</i>	207
<i>SUMAVEL™ DosePro™ needle-less injection</i>	207
Transdermal drug delivery for pain	207
<i>Relief of pain associated with minor medical procedures</i>	207
<i>Transdermal fentanyl</i>	208
<i>Transdermal ketoprofen</i>	209
<i>Transdermal nitroglycerine as an adjuvant to opioids</i>	210
<i>Transdermal buprenorphine</i>	210
<i>Transdermal trans-capsaicin</i>	210
<i>Powder Injection Systems</i>	210
Intranasal delivery of analgesics	211
<i>Intranasal morphine</i>	211
<i>Intranasal morphine derivatives</i>	212
<i>Intranasal fentanyl</i>	213
<i>Intranasal buprenorphine</i>	213
<i>Intranasal ketamine</i>	213
<i>Intranasal ketorolac</i>	214
<i>Nasal formulations for migraine</i>	214
Oral spray formulations for migraine	214
Delivery of analgesics by inhalation	214
Buccal transmucosal and sublingual delivery of analgesics	215
<i>Application for cancer pain</i>	215
<i>Application for non-cancer pain</i>	216
Pumps for drug delivery in pain	216
<i>Patient controlled analgesia</i>	217
<i>Postoperative pain pumps</i>	217
<i>Chronogestic (sufentanil) Pain Therapy System</i>	218
<i>PatchPump</i>	219
Intrathecal delivery of analgesics	219
Anatomical & physiological aspects of intrathecal drug delivery	219
Pharmacokinetics of intrathecal drug delivery	221
Epidural drugs	221

<i>Pharmacokinetics of analgesic drugs following epidural injection</i>	221
<i>Epidural glucocorticoids</i>	222
<i>Epidural etanercept</i>	222
<i>Epidural morphine</i>	222
Intrathecal drugs	222
<i>Intrathecal adenosine</i>	224
<i>Intrathecal baclofen</i>	224
<i>Intrathecal fadolmidine</i>	224
<i>Intrathecal lidocaine</i>	225
<i>Intrathecal magnesium sulfate</i>	225
<i>Intrathecal midazolam</i>	225
<i>Intrathecal opioids</i>	225
<i>Intrathecal neostigmine</i>	226
<i>Intrathecal octeoride</i>	227
<i>Intrathecal non-NMDA antagonists</i>	227
<i>Intrathecal prostaglandin antagonists</i>	227
<i>Intrathecal resiniferatoxin</i>	227
<i>Intrathecal ziconotide</i>	228
Combinations of intrathecal agents for relief of pain	228
Pumps for intrathecal delivery of analgesics	229
Complications of intrathecal delivery of analgesics	229
Concluding remarks on intrathecal delivery of analgesic agents	230
Intracerebroventricular morphine for pain	230
Development of drug delivery systems for pain therapy	231
Delivery of analgesics to the CNS across the blood brain barrier	231
Drug delivery systems in clinical trials	231

6. Drug Development for Pain..... **235**

Introduction	235
Drugs in development for pain	235
Current research goals	236
The ideal analgesic.....	236
Pain R & D goals in the pharmaceutical industry	236
Drug targets in the spinal cord	237
Drug targets in the brain	237
Molecular targets for analgesic drugs	237
Activation of P2X7 receptors.....	237
Alfa2-adrenergic receptor agonists	238
Angiotensin II type 2 receptor	238
Anti-NGF strategies	238
Bradykinin antagonists	238
Cannabinoids.....	239
<i>Cannabinoid receptor agonists</i>	239
<i>Cannabidiol</i>	241
<i>Cannabinor</i>	242
<i>Nabilone</i>	242
Capsaicin and VR1 receptor-based analgesics	243
<i>Vanilloid (capsaicin) receptor antagonists</i>	243
<i>VR1 receptor agonists</i>	243
CCR2 receptor blockade.....	244
Cholecystokinin antagonists	244
Cholinergic receptor agonists.....	244
Conotoxins as analgesics	245
Corticotropin-releasing factor	246
FAAH inhibitors.....	246
<i>PF-3845</i>	247
<i>URB597</i>	247
FKBP51 as a target for treatment of chronic pain	247
Free radical scavengers as analgesics	248
<i>Superoxide dismutase mimetics</i>	248
GABA analogues	248
<i>Subtype-selective GABAergic drugs</i>	249
Glutamate receptor antagonists	249
<i>NMDA receptor modulation for neuropathic pain</i>	249
<i>Alternatives to direct blocking of NMDA receptors</i>	250
<i>Glycine antagonists</i>	250
<i>Metabotropic glutamate receptors</i>	250
Histogranin-like compounds for the management of pain	251
Ion channels as targets for analgesic drugs	251
<i>Acid-sensing ion channels as drug target</i>	251
<i>Calcium channel blockers</i>	252

<i>HCN1 channels as targets for propofol analogs for neuropathic pain</i>	252
<i>P2X ion channel receptor antagonists</i>	253
<i>Sodium channel modulation</i>	253
Mas-related GPCR agonists.....	254
Microsomal prostaglandin E synthase inhibitors	254
NAALADase inhibitors	255
Neuropeptide receptor antagonists for improving the efficacy of opioids.....	256
Neurotrophic factor-based pain therapeutics.....	256
<i>Glial cell line-derived neurotrophic factor</i>	256
<i>Nerve growth factor antagonists</i>	256
Newer COX inhibitors	257
<i>COX-3 inhibitors</i>	257
<i>Dual cyclooxygenase/lipoxygenase inhibitors</i>	257
Nicotinic acetylcholine receptors	257
<i>Mode of action of nACh/neural nicotinic receptor agonists</i>	258
<i>Potential of central nACh/neural nicotinic receptor agonists</i>	258
Nitric oxide-based analgesics.....	259
<i>Nitric oxide-releasing NSAIDs</i>	259
<i>Pharmacology of NO-SAIDs</i>	260
<i>COX-inhibiting nitric oxide donors</i>	260
<i>NO-donating structures to extend life cycle of existing analgesics</i>	261
<i>Nitric oxide mimetics</i>	261
<i>Neuronal nitric oxide synthase inhibitors</i>	261
Norepinephrine transporter inhibition	261
Opioid peptide receptors ligands	262
<i>Buprenorphine</i>	263
<i>Nociceptin</i>	263
<i>Opioids with unique receptor characteristics</i>	263
<i>Tapentadol</i>	264
Opioid analgesics acting outside the CNS	264
<i>Oliceridine</i>	264
<i>Opioid analgesics acting at peripheral receptors</i>	265
<i>Peripherally acting mu-opioid receptor agonists</i>	265
<i>Targeting of opioid peptide-containing immune cells</i>	265
<i>Advantages of peripherally selective opioid drugs</i>	266
Resolvins	266
Somatostatin analogs	266
Substance P and neurokinin receptor antagonists.....	266
Substance P-Saporin	267
Targeting prostanoid synthesis	268
Tetrodotoxin based analgesics	268
TRPV1 modulators.....	269
<i>TRPV1 antagonists</i>	269
<i>TRPV1 agonists</i>	270
<i>TRPV1-mediated entry of sodium channel blocker QX-314</i>	270
<i>TRPV1 receptors regulate longevity</i>	271
Tumor necrosis factor- α antagonists.....	271
Biological therapies for pain	272
Cell therapy for pain	272
Cells for delivery of antinociceptive molecules	273
Cell therapy for low back pain.....	273
Cell therapy for knee pain due to degenerative disorders	274
Cell therapy for peripheral neuropathic pain	274
Cell transplantation for relief of pain.....	274
<i>Transplantation of chromaffin cells</i>	274
<i>Transplantation of stem cells</i>	275
<i>Transplantation of astrocytes secreting enkephalin</i>	275
<i>Transplantation of cells for relief of neuropathic pain</i>	275
Concluding remarks on cell therapy for pain	276
Gene therapy for pain	277
Rationale of gene therapy for pain	277
<i>Gene therapy of peripheral neuropathy</i>	277
<i>Gene therapy targeted to neuroimmune component of chronic pain</i>	278
Methods of gene delivery for pain	278
Vectors for gene therapy of pain	279
<i>Vectors for endogenous analgesic production in cranial neuralgias</i>	279
Methods of gene delivery for pain	280
<i>Gene delivery by intrathecal route</i>	280
<i>Gene transfer to the dorsal nerve roots</i>	280
<i>Gene transfer by injections into the brain substance</i>	281
Antisense therapy for pain	281

RNAi-based approaches for pain therapy	282
Potential applications of gene therapy for management of pain	283
<i>Gene therapy for producing enkephalin to block pain signals</i>	283
<i>Gene therapy for upregulation of BMP in backache</i>	285
<i>Gene therapy for targeting nuclear factor-κB</i>	285
<i>Gene therapy for neuropathic pain</i>	285
<i>Zinc finger DNA-binding protein therapeutic for chronic pain</i>	286
Concluding remarks about gene therapy for pain	286
Preclinical development of pain drugs	287
NGF-blocking antibody	287
Prostatic acid phosphatase as a novel analgesic	288
Preclinical development of drugs for neuropathic pain	288
5-HT receptor agonists	289
A-803467	289
α 9 α 10 antagonists	289
AM1241	290
Artemin/Neuroblastin	290
Capsazepine	291
Central nACh receptor agonists	291
CGP 35024	291
Cortistatin	292
Drugs that suppress glial activation	292
Erythropoietin	293
NO donating GABA-agonist drugs	293
Resiniferatoxin	293
Targeting tumor necrosis factor	294
Future targets for osteoarthritic pain	294
Pain drugs in clinical trials	294
Clinical trials of miscellaneous drugs for pain	295
Alvimopan	296
Asimadoline	297
EN3202	297
Oxytrex	297
Drugs in clinical trials for postsurgical pain	298
Bicifadine	299
DepoMorphine	299
Cox-2 inhibitors in clinical trials	300
Clinical trials of disease modifying therapies for arthritis	300
Drugs in clinical development for neuropathic pain	302
Adenosine A1 agonists for neuropathic pain	304
Ajulemic acid	305
AVP-923 (dextromethorphan + quinidine)	305
Botulinum toxin type A	305
Carisbamate	306
CNV1014802	306
D-amino acid oxidase inhibitors	306
Glyx-13	306
IP-751	307
Lacosamide	307
Oxcarbazepine	307
Perampanel	308
Ralfinamide	308
Retigabine	308
SB-509	308
TC-6499	309
Tebanicline	309
Tezampanel	309
Thalidomide	309
TRO19622	310
V3381 (indantadol)	310
XP-13512	310
Zonisamide	311
Drug discovery and development for migraine	311
Drugs in clinical development for treatment of migraine	312
Clinical development of preventive therapies for migraine	315
Monoclonal antibodies targeting CGRP for migraine prophylaxis	315
Drug development for visceral pain	316
7. Safety, Regulatory and Legal issues of pain management	317
Safety issues of analgesics	317
Adverse effects of analgesics	317

Gastrointestinal adverse effects of NSAIDs.....	317
<i>Measures to reduce gastrointestinal adverse effects of NSAIDs</i>	317
Cardiovascular adverse effects of COX-2 inhibitors.....	317
Adverse effects of opioids	318
<i>Addiction and development of tolerance</i>	318
<i>Chronic pain and opioid addiction</i>	319
<i>Abuse-deterrent opioid products</i>	320
<i>Problems and limitations of abuse-deterrent opioids</i>	321
<i>Complications of opioid abuse in the elderly</i>	322
<i>Hyperalgesia associated with opioids</i>	322
<i>Narcotic bowel syndrome</i>	323
<i>Opioid use disorder</i>	323
<i>Opioid withdrawal</i>	324
<i>Opioid-associated constipation</i>	324
<i>Respiratory depression</i>	324
Role of opioid prescribing patterns of physicians	324
Adverse effects of use of opioids in non-malignant pain	325
<i>Pharmacogenetics of adverse effects of codeine</i>	325
<i>PEGylated naloxol</i>	326
<i>Innovative approaches to modify opioid pharmacology</i>	326
Adverse effects of miscellaneous non-narcotic analgesics	326
<i>Adverse effects of immunosuppressants used for relief of pain</i>	326
<i>Adverse effects of acetaminophen</i>	327
<i>Hyponatremia as an adverse effect of tramadol</i>	327
Regulatory issues	327
Opioids.....	327
DEA and use of opioids for pain relief in terminal care	327
Cannabinoids.....	328
FDA and COX-2 inhibitors.....	328
Legal issues of COX-2 inhibitors	329
Regulatory aspects of opioid safety and abuse	329
Opioid misuse and regulatory agencies	329
FDA measures for safety of opioid use	330
Misuse of fentanyl	331
Regulation of extended release and long-acting opioids	331
Pain relief as a legal right	333
Pain relief and the WHO.....	333
8. Pain Markets.....	335
Introduction	335
Epidemiological basis of pain markets	335
Cancer.....	336
Neuropathic pain.....	336
Trigeminal neuralgia.....	336
Arthritis	336
Backache	336
Migraine	337
Multiple sclerosis.....	337
Irritable bowel syndrome	337
Chronic pelvic pain	337
Chronic pain due to traumatic brain injury	337
Postsurgical pain.....	338
Economics of pain	338
Pain as a driver of healthcare costs	338
Disability and financial loss through pain.....	339
Pain markets based on painful conditions.....	339
The cancer pain market	339
The arthritis pain market	340
Postsurgical pain market.....	340
The backache market	340
The headache market.....	341
Neuropathic pain market.....	341
Fibromyalgia market	342
Pain markets based on drugs.....	342
Opioids.....	342
Nonsteroidal antiinflammatory drugs	343
Transdermal pain therapeutics.....	343
Anesthesia	343
Antiepileptic drugs as analgesics	343
Other drugs.....	344
Hospital vs retail share of pain market.....	344

<i>Hospital versus retail opioid market</i>	344
Devices for pain.....	344
Pain markets according to geographical areas	344
Cost effectiveness of various approaches	345
Unfulfilled R&D needs in pain therapy	346
Under treatment of pain.....	346
Unfulfilled needs in drug development for chronic pain.....	346
Strategies for developing pain markets	347
Finding alternatives to intrathecal administration for chronic pain.....	347
Development of other applications of analgesic drugs.....	347
Partnership of patients, pharmacists and companies.....	348
Factors that may influence future pain markets	348
Drivers of pain markets.....	348
Public surveys as indicators of impact of pain on people.....	349
Effect of regulatory reviews on markets for pain products.....	349
Novel versus older therapies for pain.....	350
9. Future of Pain Therapeutics	351
Introduction	351
Advances in the understanding of pain	351
Pathogenesis of chronic pain.....	351
Role of glia in neuropathic pain.....	351
Molecular and neurobiological techniques.....	352
Improved understanding of cancer pain.....	353
Advances in drug discovery and development for pain	353
Novel targets for drug discovery for pain.....	353
<i>PTH2 receptor</i>	353
<i>Modulators of endogenous cannabinoids</i>	354
Application of new technologies to pain therapeutics.....	354
<i>Application of nanobiotechnology to pain therapeutics</i>	355
<i>Technologies for the manufacture of analgesics</i>	356
Future trends and needs in pain management	356
Pain management in future healthcare systems	357
Systems biology approach to pain	357
Personalized management of pain	358
Genetic factors in response to pain.....	359
Genetic mutations with loss of pain.....	360
Genetic mutations and painful conditions.....	360
Mechanism-specific management of pain.....	360
Pharmacogenomics and pharmacogenetics of pain.....	361
Personalized management of pain with commonly used analgesics.....	361
<i>Pharmacogenomics and pharmacogenetics of opioids</i>	361
<i>Pharmacogenetics of NSAIDs</i>	362
Preoperative testing to tailor postoperative analgesic requirements.....	362
Role of conditioned pain modulation in personalized management of pain.....	363
Signature of pain on brain imaging.....	363
Strategies for improving pain management	364
Research on pain in Europe	364
10. Companies Involved in Pain Therapeutics	367
Introduction	367
Profiles of companies	367
Collaborations	547
11. References	553

Tables

Table 1-1: Landmarks in the history of pain therapeutics.....	22
Table 1-2: Classification of pain.....	24
Table 1-3: Classification of neuropathic pain.....	26
Table 1-4: Classification of chronic cancer pain according to cause.....	28
Table 1-5: Percentage of patients with pain according to the type of cancer.....	29
Table 1-6: Key molecular elements of pain in the peripheral nervous system.....	52
Table 1-7: Key molecular elements of pain in the central nervous system.....	53
Table 2-1: IASP guidelines for the use of animals in pain studies.....	66
Table 2-2: Chronic pain as a manifestation of other diseases.....	67
Table 2-3: Recommendations for assessing patient satisfaction with pain management.....	73
Table 3-1: Classification of some currently used pain medications according to mechanism.....	79

Table 3-2: Drugs used for the treatment of pain	79
Table 3-3: Selective COX-2 inhibitors in clinical use for pain.....	81
Table 3-4: Antiepileptic drugs with analgesic effect	96
Table 4-1: Non-pharmacological approaches to management of pain	108
Table 4-2: Companies involved in neuromodulation therapy for pain	114
Table 4-3: Reasons for the inadequate management of acute pain.....	118
Table 4-4: Monoclonal antibodies as disease modifying therapies in rheumatoid arthritis	136
Table 4-5: Causes of chronic backache	137
Table 4-6: Management of chronic pelvic pain	141
Table 4-7: Management of pain in cancer	141
Table 4-8: Definitions of tolerance, physiological dependence, withdrawal and addiction.....	148
Table 4-9: A simplified classification of headache.....	148
Table 4-10: Various methods for the management of migraine.....	152
Table 4-11: Evidence-based level of choice of drugs for prophylaxis of migraine.....	157
Table 4-12: Management of neuropathic pain based on mechanism and diagnosis	161
Table 4-13: Management of central neuropathic pain	164
Table 4-14: Current management of peripheral diabetic neuropathy	168
Table 4-15: Treatment strategies for postherpetic neuralgia.....	170
Table 4-16: Management of complex regional pain syndrome.....	172
Table 4-17: Methods of treating phantom limb pain	174
Table 4-18: Treatment of chronic unexplained pain due to central sensitization	181
Table 4-19: Anti-itching therapies.....	181
Table 4-20: Suggested improvements in the management of pain	195
Table 5-1: A classification of drug delivery methods used in management of pain.....	199
Table 5-2: Selected marketed non-injection drug delivery systems for pain	204
Table 5-3: Approved drugs for spinal administration for pain.....	222
Table 5-4: Off-label intrathecal use of drugs for for pain.....	223
Table 5-5: Experimental studies of intrathecal administration of drugs for analgesia	223
Table 5-6: Intrathecal drugs for pain in clinical trials	223
Table 5-7: Comparison of pharmacokinetics of lipophilic with hydrophilic opioids	225
Table 5-8: Delivery systems for pain (other than intrathecal) in clinical development	232
Table 6-1: Classification of drugs in development for pain.....	235
Table 6-2: Preclinical studies on cannabinoid (CB2) receptor agonists as analgesics.....	240
Table 6-3: Cannabinoid receptor agonists in clinical development as analgesics.....	241
Table 6-4: NO-related therapies for pain.....	259
Table 6-5: Major opioids receptors and their ligands	262
Table 6-6: Strategies to counteract pain at various levels at periphery and in the CNS	268
Table 6-7: Types of TRPV1 antagonists.....	269
Table 6-8: TRPV1 antagonists in clinical trials.....	270
Table 6-9: Biological therapies for pain.....	272
Table 6-10: Experimental gene therapy approaches for relief of pain.....	278
Table 6-11: Selected preclinical approaches to pain therapy.....	287
Table 6-12: Selected preclinical drugs for neuropathic pain	288
Table 6-13: Selected clinical trials of miscellaneous drugs for pain	295
Table 6-14: Selected clinical trials of drugs for postsurgical pain.....	298
Table 6-15: COX-2 inhibitors in clinical development	300
Table 6-16: Disease modifying drugs for arthritis in clinical trials	300
Table 6-17: Clinical trials of drugs for neuropathic pain	302
Table 6-18: Selected drugs in clinical development for migraine	312
Table 6-19: Clinical trials of anti-CGRP monoclonal antibodies for migraine prevention	316
Table 6-20: Therapeutic targets for treating visceral pain	316
Table 7-1: Abuse-deterrent opioid products	321
Table 7-2: Diagnostic criteria for an opioid-use disorder	323
Table 8-1: Market values for various painful conditions 2016-2026	339
Table 8-2: Changes in market shares of drugs for neuropathic pain 2016-2026.....	341
Table 8-3: Markets for pain according to therapies 2016-2026	342
Table 8-4: Distribution of value of pain therapeutics in major markets 2016-2026	345
Table 8-5: Distribution of value of opioids in major pain markets 2016-2026.....	345
Table 8-6: Distribution of value of NSAIDs in major pain markets 2016-2026.....	345
Table 8-7: Strategies for developing pain markets	347
Table 9-1: P450 isoforms in the metabolism of drugs used in the management of pain.....	361
Table 10-1: Top companies in pain therapeutics	367
Table 10-2: Product pipeline of Adolor Corporation	374
Table 10-3: Selected collaborations in the area of pain management	547

Figures

Figure 1-1: Afferent pain pathways	31
Figure 1-2: Evolution of the gate control theory	33
Figure 1-3: The body self-neurometric.....	33

Figure 1-4: Various ligands and receptors on the peripheral terminals of nociceptive nerve fibers	53
Figure 1-5: Prostaglandin biosynthesis pathway	57
Figure 2-1: Biopsychosocial factors that interact and modulate the experience of pain.....	68
Figure 2-2: Pain intensity scales	69
Figure 3-1: Pathway of metabolism of codein	88
Figure 4-1: The WHO step ladder for pain	144
Figure 4-2: An algorithm for the acute management of migraine	153
Figure 4-3: Neuroimmune activation events leading to sensitization of CNS	160
Figure 4-4: An algorithm for the management of peripheral neuropathic pain.....	173
Figure 4-5: Algorithm for management of patients with chronic pain and depression.....	178
Figure 5-1: Powder Injection Systems	211
Figure 5-2: Penetration of CSF into spinal cord	220
Figure 5-3: Disposition of opioids after intrathecal administration	221
Figure 6-1: Attributes of the ideal analgesic	236
Figure 6-2: Nerve targeting drug delivery system for gene therapy of pain	284
Figure 8-1: Unfulfilled needs in the treatment for chronic pain.....	346
Figure 9-1: Impact of new technologies on pain therapeutics	355
Figure 9-2: Essential components of personalized management of pain	358
Figure 9-3: Genetic and non-genetic factors affecting efficacy and side effects of opioids.....	361